Nebenwirkungen · Olanzapine Glenmark Europe
Olanzapine Glenmark Europe 20 mg orodispersible tablets · Abschnitt 4.8 · PDF-Seite 53–54
HOS-211302 · Präparat HOS-154655
53 effects including Salivary constipation and hypersecretion11 dry mouth Hepatobiliary disorders Transient, Hepatitis (including asymptomatic hepatocellular, elevations of cholestatic or mixed hepatic liver injury)11 aminotransferases (ALT, AST), especially in early treatment (see section 4.4) Skin and subcutaneous tissue disorders Rash Photosensitivity Drug reaction Reaction Alopecia with Eosinophilia and Systemic Symptoms (DRESS) Musculoskeletal and connective tissue disorders Arthralgia9 Rhabdomyolysis11 Renal and urinary disorders Urinary incontinence, urinary retention Urinary hesitation11 Pregnancy, puerperium and perinatal conditions Drug withdrawal syndrome neonatal (see section 4.6) Reproductive system and breast disorders Erectile dysfunction Amenorrhea Priapism12 in males Breast enlargement Decreased libido in Galactorrhea in males and females females Gynaecomastia/breast enlargement in males General disorders and administration site conditions Asthenia Fatigue Oedema Pyrexia10 Investigations Elevated Increased alkaline Increased total plasma phosphatase10 bilirubin prolactin High creatine levels8 phosphokinase11 High Gamma Glutamyltransferase 10
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T01:00:00Z · SHA-256 3385ebe3ca7a68a60feca3a8291940e24a6aa51ddf5c7200424a88297e096b8b · Passage 767cf7cb5761c25f6f3f339f0775df9ad3ed3d6b9c64dad875b49a2695e19eb9 · Zeichen 4049–7145 im Abschnitt